Q1 2023 EPS Estimates for Viridian Therapeutics, Inc. (NASDAQ:VRDN) Lowered by Analyst

Viridian Therapeutics, Inc. (NASDAQ:VRDNGet Rating) – Investment analysts at B. Riley lowered their Q1 2023 earnings estimates for shares of Viridian Therapeutics in a research note issued on Monday, January 9th. B. Riley analyst K. Patel now forecasts that the company will earn ($1.01) per share for the quarter, down from their previous estimate of ($0.93). The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($3.55) per share. B. Riley also issued estimates for Viridian Therapeutics’ Q2 2023 earnings at ($1.08) EPS, Q3 2023 earnings at ($1.12) EPS, Q4 2023 earnings at ($1.16) EPS and FY2023 earnings at ($4.37) EPS.

Several other brokerages have also recently weighed in on VRDN. SVB Leerink upped their price target on shares of Viridian Therapeutics from $40.00 to $45.00 and gave the stock an “outperform” rating in a research report on Monday. Cowen assumed coverage on shares of Viridian Therapeutics in a research note on Monday, December 19th. They set an “outperform” rating for the company. HC Wainwright assumed coverage on shares of Viridian Therapeutics in a research note on Thursday, December 1st. They set a “buy” rating and a $35.00 price objective for the company. Credit Suisse Group assumed coverage on shares of Viridian Therapeutics in a research note on Friday, December 16th. They set an “outperform” rating and a $51.00 price objective for the company. Finally, Cowen assumed coverage on shares of Viridian Therapeutics in a research note on Monday, December 19th. They set an “outperform” rating and a $45.00 price objective for the company. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $44.60.

Viridian Therapeutics Price Performance

Shares of VRDN opened at $36.02 on Thursday. The company has a 50 day moving average price of $25.82 and a 200-day moving average price of $20.81. Viridian Therapeutics has a fifty-two week low of $9.47 and a fifty-two week high of $36.23. The stock has a market capitalization of $1.03 billion, a PE ratio of -8.54 and a beta of 0.83. The company has a debt-to-equity ratio of 0.02, a quick ratio of 17.35 and a current ratio of 17.35.

Viridian Therapeutics (NASDAQ:VRDNGet Rating) last announced its quarterly earnings results on Monday, November 14th. The company reported ($0.86) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.01. Viridian Therapeutics had a negative net margin of 6,009.30% and a negative return on equity of 109.29%. The firm had revenue of $1.20 million during the quarter, compared to analysts’ expectations of $0.52 million.

Insider Buying and Selling at Viridian Therapeutics

In other Viridian Therapeutics news, General Counsel Lara Meisner sold 8,125 shares of the company’s stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $22.05, for a total transaction of $179,156.25. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Viridian Therapeutics news, General Counsel Lara Meisner sold 8,125 shares of the company’s stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $22.05, for a total transaction of $179,156.25. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Barrett Katz sold 47,377 shares of the company’s stock in a transaction that occurred on Tuesday, January 10th. The shares were sold at an average price of $35.30, for a total transaction of $1,672,408.10. The disclosure for this sale can be found here. In the last quarter, insiders have sold 73,655 shares of company stock worth $2,362,370. 4.48% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. PDT Partners LLC increased its stake in shares of Viridian Therapeutics by 14.1% in the first quarter. PDT Partners LLC now owns 14,390 shares of the company’s stock worth $266,000 after acquiring an additional 1,775 shares during the period. Silverarc Capital Management LLC increased its stake in shares of Viridian Therapeutics by 1.9% in the first quarter. Silverarc Capital Management LLC now owns 126,136 shares of the company’s stock worth $2,332,000 after acquiring an additional 2,330 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Viridian Therapeutics in the third quarter worth $77,000. Tower Research Capital LLC TRC increased its stake in shares of Viridian Therapeutics by 189.0% in the third quarter. Tower Research Capital LLC TRC now owns 8,173 shares of the company’s stock worth $167,000 after acquiring an additional 5,345 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in shares of Viridian Therapeutics by 43.2% in the first quarter. JPMorgan Chase & Co. now owns 18,666 shares of the company’s stock worth $345,000 after acquiring an additional 5,633 shares during the period.

About Viridian Therapeutics

(Get Rating)

Viridian Therapeutics, Inc, a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED.

Featured Stories

Earnings History and Estimates for Viridian Therapeutics (NASDAQ:VRDN)

Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.